Autolus Therapeutics Raises 2026 Revenue Guidance, Extends Cash Runway

What Happened

• On August 3, 2026 Autolus Therapeutics plc filed an 8-K (press release furnished as Exhibit 99.1) announcing an increase in full-year 2026 net product revenue guidance for AUCATZYL (obe-cel; obecabtagene autoleucel) to $140 million–$150 million (previously $120 million–$135 million).
• The company also disclosed anticipated Q2 2026 net product revenue and an expected gross margin percentage for AUCATZYL sales in the first half of 2026, announced a new credit facility, and said that, based on current plans including AUCATZYL revenue and proceeds from the credit facility, cash, cash equivalents and marketable securities are expected to fund operations into the second quarter of 2028.

Key Details

• Increased 2026 AUCATZYL net product revenue guidance: $140M to $150M (prior range $120M to $135M).
• Cash runway: company expects current and projected cash, equivalents and marketable securities (plus credit facility proceeds) to fund operations into Q2 2028.
• Filing: press release dated August 3, 2026 furnished as Exhibit 99.1 to the Form 8-K.
• Forward-looking statements: the 8-K includes customary cautionary language about risks and uncertainties and refers investors to the company’s 2026 Form 10-K risk factors.

Why It Matters

• Revenue guidance raise signals stronger-than-expected commercial performance of AUCATZYL, which can affect near-term revenue forecasts and investor expectations.
• The extended cash runway into Q2 2028 reduces immediate financing pressure and gives management more runway to support commercialization, manufacturing and development plans.
• Investors should note the reliance on both product revenues and the new credit facility for runway and consider the company’s forward-looking disclaimers and disclosed risk factors when evaluating the update.